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In mutant superoxide dismutase (SOD1)-linked amyotrophic lateral sclerosis (ALS), accumulation of mis-
folded mutant SOD1 in spinal cord mitochondria is thought to cause mitochondrial dysfunction. Whether
mutant SOD1 is toxic per se or whether it damages the mitochondria through interactions with other mito-
chondrial proteins is not known. We previously identiﬁed Bcl-2 as an interacting partner of mutant SOD1
speciﬁcally in spinal cord, but not in liver, mitochondria of SOD1 mice and patients. We now show that
mutant SOD1 toxicity relies on this interaction. Mutant SOD1 induces mitochondrial morphological changes
and compromises mitochondrial membrane integrity leading to release of Cytochrome C only in the presence
of Bcl-2. In cells, mouse and human spinal cord with SOD1 mutations, the binding to mutant SOD1 triggers a
conformational change in Bcl-2 that results in the uncovering of its toxic BH3 domain and conversion of Bcl-2
into a toxic protein. Bcl-2 carrying a mutagenized, non-toxic BH3 domain fails to support mutant SOD1 mito-
chondrial toxicity. The identiﬁcation of Bcl-2 as a speciﬁc target and active partner in mutant SOD1 mitochon-
drial toxicity suggests new therapeutic strategies to inhibit the formation of the toxic mutant SOD1/Bcl-2
complex and to prevent mitochondrial damage in ALS.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease characterized by death of spinal and cranial motor
neurons (1). Three percent of ALS arises from mutations in
copper–zinc superoxide dismutase [SOD1 (2)] which acquires
newtoxicfunctionsnotfullydeﬁned(1).AlthoughSOD1iscyto-
solic, a portion ( 1–2%) partitions in the mitochondria (3–8).
Mitochondrial accumulation of misfolded mutant SOD1
(mutSOD1) has been proposed as one possible trigger of
mutSOD1-mediated motor neuron death (9). Mitochondrial
degeneration(10),vacuolizationandswelling(11)arepathologi-
cal features of both familial mutSOD1-linked human ALS
cases and mutSOD1 mouse models. In SOD1-G93A mice
mitochondrial degeneration precedes disease symptoms, culmi-
nating at disease onset (9,12). SOD1-G93A mice show dysfunc-
tionalmitochondriawithreducedATPproduction(13),oxidative
phosphorylation (14,15) and calcium buffering capacity (16).
Mitochondrial axonal transport is also impaired (17,18).
Mitochondrial mutSOD1 may directly damage these orga-
nelles by forming toxic aggregates (5). Nevertheless, it is
not known if aggregated mutSOD1 is per se toxic to mitochon-
dria or if, to cause toxicity, mutSOD1 engages in abnormal
interactions with other mitochondrial proteins. We identiﬁed
an aberrant interaction between mutSOD1 and Bcl-2 speciﬁc
of spinal cord mitochondria (7), and now show that to
damage the mitochondria, mutSOD1 relies on this interaction
with Bcl-2.
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regulation of mitochondrial membrane potential (19), Bcl-2
can reverse its functional phenotype and become a toxic
protein (20). Bcl-2 contains four functional motifs called
Bcl-2 homology (BH) domains (BH1–BH4) (21). The BH1
and BH2 domains are involved in pore formation; the BH3
and BH4 domains are the toxic and pro-survival domains,
respectively (20). In normally functioning non-toxic Bcl-2,
the BH1–BH3 domains form a hydrophobic pocket that
buries the BH3 domain to prevent toxic activities. Conversion
of Bcl-2 functional phenotype involves rearrangement of the
quaternary structure through reorganization of the unstruc-
tured loop region (22,23) and exposure of toxic BH3
domain. These conformational changes are induced by
binding with toxic proteins like Nur77 (23,24) or p53 (25)
or toxic reagents like gossypol (26).
Here we show that mutSOD1 converts Bcl-2 into a toxic
molecule, making it an active accomplice of its own toxicity.
In isolated mitochondria and in cells, Bcl-2 becomes an
essential target of mutSOD1 and undergoes a conformational
modiﬁcation, exposing the toxic BH3 domain. The mutSOD1-
induced conformational change in Bcl-2 is also evident in ALS
mice and patients with mutated SOD1. The ability of mutSOD1
to convert Bcl-2 into a toxic protein offers the opportunity
to design drugs that by inhibiting the binding between
mutSOD1 and Bcl-2 could restore or preserve Bcl-2 normal
conformation and function, thereby maintaining the integrity of
the mitochondria.
RESULTS
MutSOD1-mediated mitochondrial toxicity requires Bcl-2
Mitochondrial recruitment and accumulation of misfolded
mutSOD1 have been suggested to play a signiﬁcant role in
the mitochondrial dysfunction observed in ALS (1,9,12). To
determine whether mutSOD1 can directly damage the mito-
chondria, we incubated recombinant mutSOD1 (27), consist-
ing of a mixture of monomeric and oligomeric forms, with
puriﬁed mitochondria isolated from mouse spinal cord. We
found that contrary to wild type (WT), mutSOD1 impaired
the mitochondria as denoted by the release of Cytochrome C
(Fig. 1A), indicating that at least in vitro, mutSOD1 directly
damages the mitochondria. The challenge then is to identify
the mechanism of this direct toxicity.
We previously identiﬁed by immunoprecipitation an
aberrant and possibly harmful interaction between mutSOD1
and Bcl-2 in spinal cord mitochondria (7) and hypothesized
that mutSOD1-mediated toxicity depends on this interaction.
Although the nature of this interaction was recently disputed
(28), the data presented in Supplementary Material, Fig. S1
conﬁrm the genuine speciﬁcity of the SOD1/Bcl-2 association
both in mouse spinal cord (Supplementary Material, Fig. S1A)
and cultured cells (Fig. S1B). Control IgGs, corresponding to
the precipitating antibodies, failed to aspeciﬁcally
co-precipitate SOD1 and Bcl-2 in mouse spinal cord
(Supplementary Material, Fig. S1A). Moreover, the anti-
SOD1 antibody used in the immunoprecipitation did not
Figure 1. In isolated mitochondria, mutSOD1 induces Cytochrome C release only in the presence of Bcl-2. (A) Mitochondria isolated from mouse spinal cord
were incubated with 1 mM of recombinant SOD1 (WT, G93A and A4V) for 30 min. Samples were then ultracentrifuged and the mitochondrial (mitopellet) and
cytosolic (supernatant) fractions analyzed by WB with an anti-Cytochrome C antibody. Only mutSOD1 reduces Cytochrome C in the mitopellet and increases it
in the supernatant fraction. (B) Bcl-2 negative or Bcl-2 positive mitochondria isolated from HEK293T cells were incubated with recombinant SOD1-G93A as
above and Cytochrome C levels measured in supernatant by ELISA (left panel) and mitopellet by WB (right-upper panel). ELISA data are mean+SEM of four
independent experiments. Mitopellet shows a representative WB. Data were also conﬁrmed with SOD1-A4V-treated mitochondria and analyzed by WB (right-
lower panel). CaCl2 was used as control for maximal loss of mitochondrial integrity.
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in  25–30 kDa range in Bcl-2 lacking HEK293T cells (Sup-
plementary Material, Fig. S1B), attesting the speciﬁcity of the
SOD1/Bcl-2 co-immunoprecipitation and further validating
our ﬁndings.
Thus, to determine whether mutSOD1 is intrinsically toxic or
requiresBcl-2toinducemitochondrialdamage,wemeasuredthe
release of Cytochrome C from mitochondria isolated from non-
transfected HEK293T cells (Bcl-2 negative mitochondria) or
from HEK293T cells transiently transfected with Bcl-2 (Bcl-2
positive mitochondria) and incubated with recombinant
mutSOD1(A4VorG93A)asabove.AsshowninSupplementary
Material,Fig.S1C,theextensivelycharacterizedHEK293Tcells
lackdetectablelevelsofBcl-2(24)andthereforerepresentasuit-
able tool tostudy the effect ofmutSOD1 in the absence ofBcl-2.
Cytochrome C released from mitochondria was analyzed by
ELISA (Fig. 1B-supernatant), whereas the amount of Cyto-
chrome C retained in the mitochondrial pellet was determined
by western blot [WB (Fig. 1B-mitopellet)]. SOD1-G93A did
not induce a Cytochrome C release in the medium in which
the Bcl-2 negative mitochondria were suspended
(Fig.1B-supernatant).Accordingly,Bcl-2negativemitochondria
retained Cytochrome C when incubated with SOD1-G93A
(Fig. 1B-mitopellet). When incubated with Bcl-2 positive mito-
chondria (derived from Bcl-2-transfected HEK293T cells),
mutSOD1 induced a 2-fold increase in Cytochorme C released
into the supernatant (P , 0.05, Fig. 1B-supernatant). Similar
results were obtained with mutSOD1-A4V. Only in Bcl-2 posi-
tive mitochondria, incubation with SOD1-A4V led to a 40%
decreaseofCytochromeCinthemitopellet(Fig.1B-mitopellet).
Contrary to mutSOD1s, SOD1-WT did not induce a release of
Cytochrome C from either Bcl-2 negative or positive mitochon-
dria (data not shown).
The requirement of Bcl-2 for mutSOD1-mediated mitochon-
drial damage was conﬁrmed in cells in situ. HEK293T cells
were either transfected with eGFP-tagged SOD1s (WT and
G93A) as control, or co-transfected with eGFP-tagged SOD1s
and Bcl-2. Transfection with Bcl-2 alone or co-transfection
with the eGFP empty vector was also used as additional
control. Twenty-four hours after transfection, mitochondrial
integrity was determined by immunoﬂuorescence using an
anti-Cytochrome C antibody and confocal microscopy analysis.
Transfection of either Bcl-2 or SOD1 (WT and G93A) alone did
not damage the mitochondria. This is illustrated in single trans-
fected HEK293T cells by the punctate immunoﬂuorescence
indicative of Cytochrome C retention into intact mitochondria
(Fig. 2A). In contrast, in 85% of HEK293T cells co-expressing
Bcl-2 and mutant, but not SOD1-WT, there was diffuse Cyto-
chrome C immunoﬂuorescence, indicating that release of Cyto-
chrome C from damaged mitochondria had occurred (Fig. 2A
and B). Release of Cytochrome C was also detected in
mitochondrial pellets by WB (Fig. 2C). As determined by den-
sitometric analysis, Cytochorme C decreased by 35% only in
the mitochondrial pellet derived from cells expressing both
Bcl-2 and mutSOD1 (Fig. 2C-right panel). There was no signiﬁ-
cant loss of mitochondrial Cytochorme C in cells expressing
either Bcl-2 or mutSOD1 alone. Together with the evidence col-
lected in isolated mitochondria, these results indicate that
mutSOD1-mediated loss of mitochondrial integrity relies on
the presence of Bcl-2, underscoring the importance of the
mutSOD1/Bcl-2 complex in the regulation of mitochondrial
viability.
MutSOD1 and Bcl-2 induce morphological alterations
in mitochondria
To investigate if the release of Cytochrome C mediated by
mutSOD1 and Bcl-2 was accompanied by structural altera-
tions of the mitochondria, we analyzed mitochondrial mor-
phology by transmission electron microscopy in HEK293T
cells co-transfected with mutSOD1 and Bcl-2 or control
cells co-transfected with mutSOD1 + control plasmid or
Bcl-2 + SOD1-WT. Figure 3 shows results representative of
four independent experiments. For each experiment, 8–10
ﬁelds of vision were randomly photographed under the trans-
mission electron microscope. A comparison between the
experimental groups was then made by scoring the percentage
of damaged mitochondria/ﬁeld. For each experimental group,
transfection efﬁciency was determined by WB analysis of
SOD1-eGFP and Bcl-2, respectively (Fig. 3B). One hundred
percent of non-transfected, control HEK293T cells had
elongated mitochondria with intact internal structure and
cristae organization (Fig. 3A, panel A). Single transfection
of SOD1 (WT or mutant), or Bcl-2 did not induce any mor-
phological change in mitochondria [95% of mitochondria
retained intact membrane and cristae (Fig. 3A, panels B, C
and D)]. Similarly, when co-transfected with SOD1-WT,
Bcl-2 did not alter the mitochondria morphology [97% of
intact mitochondria (Fig. 3A, panel E)]. HEK293T cells
co-expressing mutSOD1 and Bcl-2 were instead characterized
by a vast majority (80%) of rounded, swollen mitochondria
with deranged cristae and extensive vacuolization (Fig. 3A,
panel F). This aberrant mitochondrial morphology in response
to co-expression of mutSOD1 and Bcl-2 was not the aspeciﬁc
consequence of protein overload due to different degrees of
transfection in the various experimental groups, as WB analy-
sis of Bcl-2 and SOD1 (WT and mutant) showed comparable
expression levels among different samples (Fig. 3B).
MutSOD1 damages the mitochondria by triggering a
conformational change in Bcl-2 which exposes the toxic
BH3 domain
Upon binding to toxic proteins like Nur77 (24) and p53 (25),
Bcl-2 gains a novel toxic function, triggered by a structural
modiﬁcation that exposes the toxic BH3 domain. To study
whether binding to mutSOD1 altered Bcl-2 conformation
exposing the toxic BH3 domain, we employed immunoprecipi-
tation and ﬂow cytometry analysis using anti-Bcl-2 (a-Bcl-2)
conformation-speciﬁc antibodies (24). We used the a-Bcl-2/
pocket, which recognizes conformationally normal Bcl-2 in
which the pocket region masks the toxic BH3 domain, the
a-Bcl-2/BH3 domain, which binds only to conformationally
altered Bcl-2 in which the toxic BH3 domain is exposed and
the a-Bcl-2 antibody, which binds to the loop domain and is
accessible in both BH3-masked and BH3-exposed Bcl-2 pro-
teins (see Supplementary Material, Fig. S2A).
We studied the effect of mutSOD1 on Bcl-2 conformation
in neuronal SH-SY5Y cells (Fig. 4A) that endogenously
express Bcl-2 and were therefore transfected with SOD1
2976 Human Molecular Genetics, 2010, Vol. 19, No. 15proteins only (WT, G37R or G93A). When compared with cells
transfected with SOD1-WT, transfection of mutSOD1 proteins
decreased the exposure of the pocket region and therefore the
amount of Bcl-2 immunoprecipitated by the a-Bcl-2/pocket
antibody, and led to an increase in Bcl-2 immunoprecipitated
by the a-Bcl-2/BH3 antibody (Fig. 4A, left panel), indicating
that in the presence of mutSOD1, Bcl-2 underwent a structural
change allowing exposure of the normally buried toxic
Figure 2. Co-expressionofBcl-2andmutant,butnotSOD1-WT,damagesthemitochondria.(A)Mitochondrialintegritywasassessedbyconfocalmicroscopyanaly-
sis ofHEK293T cells transfectedwithSOD1-eGFP(WT orG93A)inthepresence orabsenceofBcl-2 andstainedwithanti-CytochromeC antibody. For eachexper-
iment (n ¼ 4), 10 ﬁelds of vision were randomly photographed and the percentage of cells co-expressing mutSOD1 (green) and Bcl-2 (blue) with damaged
mitochondria was counted. Approximately 85% of cells show damaged mitochondria with diffuse Cytochrome C staining. In cells expressing SOD1-G93A alone,
Cytochrome C staining is punctuate, indicative of structurally intact mitochondria. In 98% of SOD1-WT-positive cells, either in the presence or absence of Bcl-2,
staining of Cytochrome C is punctuate (intact mitochondria). Scale bar 20 mm. (B) z-stack orthogonal views are shown to conﬁrm mitochondrial integrity and Cyto-
chromeCstainingwithinthecell.Scalebar20 mm.(C)RepresentativeWBofmitochondrialCytochromeC.MitochondriawereisolatedfromHEK293Tcellsandthe
totalamountofCytochromeCretainedand/orreleasedfromthemitopelletassessedbyWB.MutSOD1andBcl-2induceadecreaseofCytochromeCinmitochondria,
whereas expression of either molecule alone does not (top lane). Efﬁciency of transfection was evaluated by probing for Bcl-2 (bottom lane). The histogram shows
intensity of Cytochrome C staining in mitopellet measured by densitometric analysis using the Biorad Chemidoc Quantity One software. Data are mean (mean +
SEM) of three independent experiments. Student’s t-test shows statistically signiﬁcant differences between experimental groups. EV ¼ empty vector.
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The ratio BH3/pocket increased in the presence of
mutSOD1, whereas it remained virtually unchanged in cells
transfected with SOD1-WT (Fig. 4A, right panel). The fact
that two different mutSOD1 proteins (G37R and G93A)
induced a similar conformational change in Bcl-2 indicates
that the exposure of the toxic BH3 domain in the mutSOD1/
Bcl-2 complex is a shared feature among ALS-linked SOD1
mutants. We conﬁrmed this by ﬂow cytometry (Supplemen-
tary Material, Fig. S2B) in SH-SY5Y cells transiently trans-
fected with eGFP-tagged SOD1-G37R and G93A. In
agreement with the immunoprecipitation experiments, Bcl-2/
BH3 immunoﬂuorescence was absent in non-transfected
cells (Supplementary Material, Fig. S2B) and negligible in
eGFP expressing cells used as mock-transfected control (not
shown). A signiﬁcant Bcl-2/BH3 immunoﬂuorescence was
instead detected in both SOD1-G37R and G93A transfected
cells (Supplementary Material, Fig. S2B), conﬁrming the con-
formational change in Bcl-2 triggered by mutSOD1.
In mutSOD1 ALS mice and patients Bcl-2 undergoes a
conformational change that exposes the toxic BH3 domain
We next studied whether exposure of the toxic BH3 domain
occurs in vivo and extended our analysis to the well-
characterized SOD1-G93A mouse model of ALS. Immunopre-
cipitationandWBanalysisofspinalcordhomogenatesprepared
from 130-day-old SOD1-G93A mice (end-stage), showed a
signiﬁcant exposure of the toxic BH3 domain compared with
spinal cord homogenates prepared from age-matched
SOD1-WT over-expresser mice (Fig. 4B). Exposure of the
toxic BH3 domain was paralleled by a decrease in binding afﬁ-
nity for the Bcl-2/pocket domain reﬂecting a loss of the normal
protective function of Bcl-2. This Bcl-2 structural confor-
mational change increased as disease progressed in the
SOD1-G93A mice (Fig. 4C), appearing in 30-day-old pre-
symptomatic mice and peaking at disease onset (85 days). Den-
sitometric analysis of the immunoprecipitated Bcl-2 (Fig. 4C,
right panel) showed that the ratio BH3/pocket reverses during
progression of the disease, with the minimum BH3 exposure
at 30 days (early pre-symptomatic stage) and the highest at
disease onset (85 days). This gradual appearance (Fig. 4C,
right panel) of the toxic BH3 domain strongly suggests the
disease speciﬁcity of the conformational change in Bcl-2.
A similar conformational modiﬁcation in Bcl-2 was seen in
a spinal cord homogenate prepared from an SOD1-A4V ALS
patient (Fig. 4D).
Co-expression of mutSOD1 and BH3-inactive Bcl-2 no
longer damages mitochondria and does not compromise
cell viability
To conﬁrm that exposure of the toxic BH3 domain is a relevant
mechanism in mutSOD1-induced mitochondrial damage, we
Figure 3. Co-expression of SOD1-G93A and Bcl-2 induces mitochondrial structural damage. (A) Electron microscopy analysis of mitochondrial structure in
HEK293T transfected with SOD1-WT (panels C and D), SOD1-G93A (panels E and F) without (upper panels A, C and E) or with (lower panels B, D and
F) Bcl-2. Cells transfected with SOD1-G93A alone show structurally normal mitochondria (panel E), whereas co-expression of Bcl-2 and SOD1-G93A
causes morphological changes as shown by extensive internal vacuolization and cristae disorganization (panel F). Images are representative of four experiments.
(B) Transfection efﬁciency and expression levels of SOD1-eGFP and Bcl-2 among different experimental groups were assessed by WB with an anti-eGFP and
Bcl-2 antibody, respectively.
2978 Human Molecular Genetics, 2010, Vol. 19, No. 15generatedaBcl-2inwhichtheBH3domainhasbeeninactivated
by mutating its core sequence (Gly
101–Asp
102–Asp
103
 Ala
101–Ala
102–Ala
103). This mutated Bcl-2(AAA) has
been previously described to lose its ability to induce cellular
toxicity and Cytochrome C release (29).
Whereas HEK293T cells co-expressing mutSOD1 and
BH3-active Bcl-2 showed diffuse pattern of Cytochrome
C staining indicative of damaged mitochondria (Fig. 2),
HEK293T cells co-transfected with mutSOD1 and Bcl-2/
BH3-inactive displayed Cytochrome C punctate staining
Figure 4. MutSOD1s induce a conformational change in Bcl-2 leading to exposure of the toxic BH3 domain in cells, mouse and human spinal cords. (A)
SH-SY5Y cells, which express endogenous Bcl-2, were transfected with SOD1 (WT, G37R or G93A) and Bcl-2 conformation assessed by immunoprecipitation
with the a-Bcl-2/BH3 and a-Bcl-2/pocket antibody, respectively. Immunoprecipitated proteins were analyzed by WB with anti-Bcl-2 antibody against the N-
terminal domain (left panel). Total amount of Bcl-2 was assessed by WB (left panel, bottom lane). In the presence of mutSOD1s (G37R and G93A), there is an
increased exposure of the toxic BH3 domain paralleled by a decrease in the pocket region. The plot in the right panel shows the ratio BH3/pocket as analyzed by
densitometric analysis of the immunoprecipitated Bcl-2 with the Quantity One software. (B) The a-Bcl-2/BH3 and a-Bcl-2/pocket antibodies were used to
immunoprecipitate Bcl-2 from spinal cord homogenates of 130-day-old transgenic mice expressing either SOD1-WT or SOD1-G93A. In SOD1-G93A mice
there is an increased exposure of the toxic BH3 domain of Bcl-2 compared with age-matched transgenic SOD1-WT mice, and this is paralleled by a decreased
exposure of the pocket. (C) Conformational changes in Bcl-2 were then assessed over time in the SOD1-G93A mice. Exposure of the toxic BH3 domain appears
prior to and peaks at disease onset (left panel). Densitometry analysis of the ratio BH3/pocket is shown in the plot on the right. (D) Immunoprecipitation of
post-mortem human SOD1-A4V spinal cord shows increased exposure of the BH3 domain (shown as ∗) paralleled by a decreased exposure of the pocket
region in human ALS.
Human Molecular Genetics, 2010, Vol. 19, No. 15 2979Figure 5. BH3-inactive Bcl-2 abolishes mutSOD1 mitochondrial toxicity. (A) Representative confocal images. HEK293T cells were transfected with
SOD1-G93A eGFP in the presence or absence of Bcl-2(AAA) for 24 h and mitochondrial integrity assessed by staining with the anti-Cytochrome C antibody.
When co-transfected with Bcl-2(AAA), SOD1-G93A loses its toxicity on mitochondria and does not trigger a release of Cytochrome C. Scale bar 20 mm. (B)
Mitochondrial integrity was also assessed with z-stack orthogonal views. Scale bar 20 mm. (C) Cytochrome C release from damaged mitochondria was conﬁrmed
biochemically. Mitochondria were isolated from HEK293T cells co-transfected with SOD1-G93A and Bcl-2(AAA) and the amount of mitochondrial Cyto-
chrome C measured in the mitopellet by WB. Cytochrome C is retained in the mitochondria in cells with SOD1-G93A and Bcl-2(AAA) (top lane), indicating
only little or no damage to the mitochondria. Efﬁciency of transfection was evaluated by probing for Bcl-2 (bottom lane). The histogram in the right panel shows
the results of densitometric analysis of mitochondrial Cytochrome C staining. Data are mean (mean + SEM) of four experiments. Student’s t-test shows stat-
istically signiﬁcant differences between experimental groups. (D) Bcl-2(AAA) retains its binding properties with SOD1-G93A. HEK293T cells were
co-transfected with SOD1-G93A and either Bcl-2 or Bcl-2(AAA), lysed and immunoprecipitated with the anti-SOD1 antibody. Binding to Bcl-2 was determined
by WB (top lane). Efﬁciency of transfection was evaluated by probing for Bcl-2 (bottom lane). (E) HEK293T cells were transfected with an empty vector
(Mock), SOD1-G93A alone or in combination with Bcl-2 or Bcl-2(AAA). SOD1-G93A induces a loss of viability in the presence of BH3-active Bcl-2, but
not in cells in which the BH3 domain is inactive. Student’s t-test was performed to determine differences between groups.
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analysis of Cytochrome C in the mitochondrial pellet derived
fromHEK293TcellsshowedreducedmitochondrialCytochrome
C only in cells co-transfected with mutSOD1 and BH3-active
Bcl-2. In cells co-transfected with mutSOD1 and Bcl-2(AAA),
Cytochrome C levels were unaffected (Fig. 5C). The absence of
mitochondrial damage in the presence of Bcl-2(AAA) is not
due to lack of binding between mutSOD1 and Bcl-2(AAA).
Co-immunoprecipitation experiments (Fig. 5D) in HEK293T
cells conﬁrmed that Bcl-2(AAA) is still able to bind and
co-precipitate with mutSOD1 (Fig. 5D).
We next studied whether inactivation of the BH3 domain is
also able to block the downstream effects of the toxic
mutSOD1/Bcl-2 complex on the viability of HEK293T cells.
We used the CellTiter-Glo Luminescent Cell Viability Assay
which measures the number of metabolically active cells/
well. As expected, co-expression of mutSOD1 and BH3-active
Bcl-2 induced a signiﬁcant loss of cell viability ( 25%)
whereas co-expression of mutSOD1 and Bcl-2(AAA) did
not. These data conﬁrm that mutSOD1-mediated toxicity pro-
ceeds through exposure of the toxic BH3 domain.
Toxicity of the mutSOD1/Bcl-2 complex is
organelle-speciﬁc
To determine whether the toxicity caused by the mutSOD1/
Bcl-2 complex required speciﬁc mitochondrial localization of
Bcl-2 within the cell, we transfected HEK293T cells with
mutSOD1 and Bcl-2 lacking its trans-membrane domain
(Bcl-2/DTM) and therefore unable to anchor itself to the outer
mitochondrial membrane. Damage of the outer mitochondrial
membrane required simultaneous mitochondrial localization
of mutSOD1 and Bcl-2 because leakage of Cytochrome C did
not occur in cells co-transfected with mutSOD1 and Bcl-2/
DTM (Fig. 6A). Although Bcl-2/DTM was present in the cells
and expressed in equal amounts compared with Bcl-2 WT
(Fig. 6A), mutSOD1 lost its toxic properties on the mitochon-
dria. Interestingly, mutSOD1 did not impair cell viability
when co-expressed with Bcl-2/DTM (Fig. 6B) strongly
arguing in favor of an organelle-speciﬁc effect of the
mutSOD1/Bcl-2 complex. Further, in H4 cells that appear to
express exclusively nuclear Bcl-2, mutSOD1 lost its mitochon-
drial toxic effect (Supplementary Material, Fig. S3), indicating
that toxicity mediated by the mutSOD1/Bcl-2 complex requires
anchoring of Bcl-2 to the mitochondrial outer membrane.
DISCUSSION
Wedissectedthemechanism(s)bywhichmutSOD1damagesthe
mitochondria. We focused on the mutSOD1/Bcl-2 interaction
because in mutSOD1 ALS mice and patients, we previously
identiﬁed this aberrant protein complex occurring in spinal
cord but not liver mitochondria (7), a pattern that correlates
with the tissue speciﬁcity of the disease. We therefore hypoth-
esizedthattodamagethemitochondriamutSOD1reliesonmito-
chondrial Bcl-2. The results presented here support this
hypothesis. We show that mutSOD1 targets mitochondrial
Bcl-2andconvertsitintoatoxicproteinthatactivelyparticipates
in mutSOD1-mediated mitochondrial toxicity.
Mitochondria degeneration is recognized as a component of
mutSOD1 toxicity in ALS. The observation that misfolded
mutSOD1 accumulates in spinal cord mitochondria (5) and
that only mitochondria with mutSOD1 inclusions degenerate
(30) suggests that these organelles are a primary target of
mutSOD1-mediated toxicity. Whether accumulation of mis-
folded mutSOD1 at the mitochondria is a secondary event of
disease progression, or whether mitochondrial mutSOD1
actively damages the mitochondria is not known. Here we
show that in vitro, addition of puriﬁed mutant, but not
SOD1-WT, to mitochondria isolated either from cultured
cells or spinal cord tissues damages the mitochondria ulti-
mately leading to Cytochrome C release. These results
provide a cause-effect link between mutSOD1 and loss of
integrity of the mitochondrial membranes, strongly suggesting
that mutSOD1 actively damages the mitochondria.
How does mitochondrial mutSOD1 damage the mitochon-
dria? Does it act alone or does it require a partner(s) in
crime? Formation of vacuoles in the outer mitochondrial
membrane (31) or protein aggregates that clog or disrupt the
TOM complex (5), could either be potential mechanisms by
which mutSOD1 alone impairs the mitochondria. Alterna-
tively, mutSOD1 could interact with other vital mitochondrial
proteins like Bcl-2 (7) and/or the recently identiﬁed mito-
KARS (32). Here we show that in the absence of Bcl-2,
mutSOD1 loses its toxic effect on isolated mitochondria, indi-
cating that rather than acting alone, mutSOD1 requires Bcl-2
to damage the mitochondria. Thus, Bcl-2 is not simply a
hostage protein, but it becomes an active accomplice of
mutSOD1-mediated mitochondrial toxicity.
Bcl-2 is an essential regulator of mitochondria viability (20);
it forms pore-like channels spanning one or both mitochondrial
membranes whose activity is to offset mitochondrial ion imbal-
ances induced by toxic stimuli or altered calcium uptake, restor-
ing the mitochondrial membrane potential (Dc)t on o r m a ll e v e l s
(33). Bcl-2 also directly binds and inhibits the toxic function of
pro-death proteins like Bax and BaK (34), and prevents swel-
ling of the mitochondrial matrix and uncontrolled production
of reactive oxygen species (20,35). Bcl-2 can also lose these
protective properties and reverse its phenotype into a lethal
protein by undergoing a conformational change which
exposes its toxic BH3 domain (22,24,29). Using conformation-
speciﬁc Bcl-2 antibodies, we demonstrated that when bound to
mutSOD1, Bcl-2 changes conformation and exposes its other-
wise hidden BH3 domain, as reported when Bcl-2 interacts
with toxic molecules like Nur77 and p53 (22). Through
exposure of the toxic BH3 domain, Bcl-2 intensiﬁes the mito-
chondrial damage caused by mutSOD1. When mutSOD1
binds to Bcl-2(AAA), a mutated form of Bcl-2 with an inactive
BH3 domain, the mitochondrial membrane remains intact, and
there is no leakage of Cytochrome C nor loss of cell viability.
Thus, mutSOD1 converts Bcl-2 into a partner in crime which,
most likely, targets surrounding mitochondrial proteins or
other pro-survival members of the Bcl-2 proteins antagonizing
and/or inhibiting their function. Studies are underway to
examine these hypotheses.
We showed that SOD1-WT binds to the N-terminal portion
of Bcl-2 between the BH4 and the loop domain (7). Although
we used multiple Bcl-2 deletion mutants covering the entire
Bcl-2 sequence, including the DBH4/loop mutant which
Human Molecular Genetics, 2010, Vol. 19, No. 15 2981abolishes the binding with SOD1-WT, we failed to identify
speciﬁc domains in Bcl-2 responsible for binding with
mutSOD1. None of the Bcl-2 deletion mutants tested abolishes
this binding, suggesting that mutSOD1 binding to Bcl-2 is
conformation-speciﬁc and likely occurs on multiple distinct
domains throughout the quaternary structure of Bcl-2. The
unstructured loop domain of Bcl-2 links the BH4 to the BH3
domain and maintains the correct (pro-survival) conformation
of Bcl-2 (23). Like other natively unstructured loops of the
same class, the Bcl-2 loop domain adapts its structure upon
different stimuli. When it is cleaved by caspases at position
34 (29,36) or when it is phosphorylated by stress-activated
kinases (37), the loop domain rearranges Bcl-2 structure, indu-
cing a conformational change. Binding of Nur77 and p53 at or
near the loop domain induces a rearrangement of the hydro-
phobic cleft of Bcl-2, masking the pocket region and unmask-
ing the toxic BH3 domain (24). Thus, if like WT, mutSOD1
binds at the interface with the loop domain but, unlike WT,
engages Bcl-2 in a conformational aberrant binding which
entraps multiple portions of the loop region, we suggest that
mutSOD1 changes Bcl-2 conformation by acting on the loop
domain, rearranging the hydrophobic cleft. Regardless,
binding to Bcl-2 occurs only after mutSOD1 docking to the
mitochondria. This is consonant with the lack of evidence
for mutSOD1 localization in the nucleus or binding to
nuclear Bcl-2 when mutSOD1 is expressed in H4 cells
(Supplementary Material, Fig. S3), and with the evidence
that mitochondria localization of Bcl-2 is required for
Figure 6. Anchoring of Bcl-2 to mitochondria is necessary for mutSOD1-induced toxicity. (A) HEK293T cells were co-transfected with SOD1-G93A and either
Bcl-2 or Bcl-2 lacking the transmembrane domain (Bcl-2 DTM). When co-transfected with Bcl-2 DTM, which does not localize in mitochondria (diffuse blue
staining), SOD1-G93A does no longer induce release of Cytochrome C. Efﬁciency of the transfection was evaluated by WB probing for Bcl-2. The integrityo f
mitochondria was also assessed by confocal analysis with z-stack orthogonal views (right). (B). HEK293T cells were transfected with empty vector (Mock),
SOD1-G93A alone or in combination with Bcl-2 or Bcl-2 DTM. SOD1-G93A induces a loss of viability in the presence of Bcl-2, but not in Bcl-2 DTM-positive
cells. Student’s t-test shows statistically signiﬁcant differences between experimental groups.
2982 Human Molecular Genetics, 2010, Vol. 19, No. 15mutSOD1 to damage mitochondria (Fig. 6). In H4 cells in
which Bcl-2 displays exclusive nuclear localization and in
HEK293T cells transfected with Bcl-2/DTM, the mitochondria
are unaffected by the presence of mutSOD1 and cells expres-
sing mutSOD1 are viable and metabolically active. This
suggests that toxicity of the mutSOD1/Bcl-2 complex is
organelle-speciﬁc and also that docking of mutSOD1 to the
mitochondria is independent of Bcl-2. Even in the absence
of mitochondrial Bcl-2, a small portion of mutSOD1 resides
in the mitochondria (Fig. 6), implying that mutSOD1 mito-
chondrial localization occurs independently of Bcl-2,
perhaps through binding to other mitochondrial proteins.
Two observations underscore the tissue-speciﬁc pathogenic
role of the mitochondrial mutSOD1/Bcl-2 complex. First, in
ALS mice and patients this complex is speciﬁcally found in
spinal cord but not liver mitochondria (7), in line with the
tissue speciﬁcity of the disease. Second, in mutSOD1-G93A
mice, the gradual conformational change in mitochondrial
Bcl-2 correlates with disease progression in the spinal cord.
We do not know whether this disease-related conformational
change in Bcl-2 is motor neuron-speciﬁc or whether, within
the spinal cord, it equally occurs in glia and neurons. The
results presented in Fig. 4B and C, where the majority of
spinal cord Bcl-2 gets converted into the toxic form in
mutSOD1-G93A mice, suggest that this conversion occurs in
virtually all cells and not only in the motor neurons as predicted
by the non-cell autonomous nature of ALS. We do not know
whether, although occurring in all cell types, formation of the
mutSOD1/Bcl-2 complex is toxic only to the most vulnerable
motor neurons or it equally damages other cells.
The conformational and phenotypic change in Bcl-2
induced by mutSOD1 may result in multiple harmful effects
that ultimately weaken the mitochondria. The newly exposed
BH3 domain may bind glutathione (GSH), inhibiting its anti-
oxidant properties (38). Alternatively, in contrast to normally
structured Bcl-2 which forms low conductance channels to
maintain physiological mitochondrial Dc (33,39), confor-
mationally altered Bcl-2 may change its channel activity and
dysregulate mitochondria bioenergetics ultimately causing
Cytochrome C release. Compared with age-matched WT
mice, pre-symptomatic SOD1-G93A and SOD1-G85R mice
show an increased mitochondrial calcium-dependent Dc
depolarization which could result in reduced ATP synthesis
at the synaptic terminals (40). Finally, binding to mutSOD1
may disrupt Bcl-2 binding to death-inducing proteins. In its
normal conformation, the BH4 domain interacts with pro-
death members of the Bcl-2 family and inhibits their toxic
function (41). Following the conformational change induced
by mutSOD1, the BH4 domain could become unavailable
for binding, failing to antagonize pro-apoptotic proteins.
We favor the hypothesis that focuses on a direct toxic func-
tion of Bcl-2 on the mitochondria rather than on its potential to
lose anti-apoptotic functions. This is because: (a) as disease
progresses mitochondrial abnormalities precede motor
neuron apoptotic death (1); (b) a recent report dissociated
motor neuron dysfunction from apoptosis in ALS (28); (c) in
neurons, after their conversion into toxic molecules,
Bcl-2-like proteins induce mitochondrial alterations and
decrease in synaptic function (42) independently from apopto-
tic mechanisms.
Since mitochondria regulate neuronal apoptosis and because
activation of apoptotic pathways has been observed in ALS
mice (1,43), the mitochondrial mutSOD1/Bcl-2 complex
described in our previous work could have been interpreted
as the mechanism by which mitochondrial mutSOD1 causes
motor neuron apoptosis. However, the signiﬁcance of apopto-
sis in ALS, and with that the signiﬁcance of the pro-apoptotic
function of the mutSOD1/Bcl-2 complex, has recently been
challenged by the observation that ALS mice lacking the
pro-apoptotic protein Bax develop motor neuron disease and
mitochondrial abnormalities even in the absence of cell
death (28). The ﬁndings presented here support rather than
contradict this notion and may contribute to explain the para-
doxical series of observations that argue against apoptotic cell
death in ALS even though loss of motor neurons is
accompanied by release of apoptogenic factors from the mito-
chondria and caspase activation (44–46). Our data suggest
that, under stressful circumstances set in motion by mitochon-
drial mutSOD1, the normally pro-surviving Bcl-2 protein
changes its phenotype, becomes toxic and destabilizes mito-
chondrial homeostasis through a mechanism independent of
the classical cell death pathway. Consistent with this, gossypol
(a polyphenolic compound shown to interact with Bcl-2)
induces Bax/Bak independent Cytochrome C release and
loss of Dc by triggering a conformational change in Bcl-2
that exposes the toxic BH3 domain in Bak
2/2/Bax
2/2 cells
(26). Similarly, in Bax
2/2SOD1-G93A mice (28), which
lack developmental apoptosis but express Bcl-2, the
mutSOD1/Bcl-2 complex may gain a new toxic function that
triggers motor neuron dysfunction by directly damaging the
mitochondria, ultimately impairing synaptic transmission at
the neuromuscular junction.
Our work shows that mutSOD1 induces a gradual change in
Bcl-2 conformation and function over time in the ALS mice.
This result may also explain why over-expression of Bcl-2
in these mice only slightly delays disease onset without affect-
ing disease duration (47). On the basis of our ﬁndings, one
would expect that adding extra Bcl-2 in its normally protective
conformation to the ALS mice would buy extra time and mar-
ginally delay disease onset. However, once the extra Bcl-2 is
bound to mutSOD1, it no longer protects the motor neurons
and instead becomes a toxic liability. Thus, our data suggest
an alternative therapeutic strategy that targets the toxic
binding between mutSOD1 and Bcl-2 instead of using Bcl-2
as a rescuing agent. BH3 and Bcl-2 like peptides are routinely
used in cancer therapy (20); our data suggest that a similar
therapeutic approach with peptides designed to compete or
displace Bcl-2 from binding mutSOD1, can be tested in
ALS mice and turned to our advantage to delay mitochondrial
dysfunction in mutSOD1-mediated ALS.
MATERIALS AND METHODS
Cytochrome C release from isolated mitochondria
Mouse spinal cords and lysates of HEK293T cells (with or
without Bcl-2, ATCC cat. # CRL-11268) were homogenized in
800 ml of Buffer A (250 mM Sucrose, 20 mM Hepes-KOH pH
7.5, 10 mM KCl, 1.5 mM MgCl2,1m M EDTA, 1 mM EGTA,
1m M DTT, protease inhibitor) and spun at 750g at 48Cf o r
Human Molecular Genetics, 2010, Vol. 19, No. 15 298310 min. The pellet was re-homogenized in 400 mlo fb u f f e rA ,
spun at 750g at 48C for an additional 10 min. The supernatants
from these two homogenization steps were combined in one sol-
utionwhichwasspuntwiceat750gat48Cfor10 minandonceat
10 000g at 48C for 15 min. Each pellet was re-suspended in
80 mlo fB u f f e rB( 7 0m M Sucrose, 190 mM Mannitol, 20 mM
Hepes, pH 7.5 with protease inhibitor). Twenty-ﬁve microliters
of mitochondria were incubated at room temperature for
30 min with either 1 mM of CaCl2 (Ca Cl2)o r1m M of recombi-
nant SOD1 (G93A or A4V oligomers, kindly provided by Drs
Andrew Choi and Peter Lansbury, Harvard Medical School) in
20 ml of Buffer B. Twenty-ﬁve microliters of untreated (CTL)
mitochondria were incubated with 20 mlo fB u f f e rB .S a m p l e s
were then spun at 100 000g for 1 h at 48C. The resulting super-
natant was then analyzed for Cytochrome C with ELISA follow-
ing the manufacturer’s instruction (R&D Systems, Minneapolis,
MN), whereas the resulting mitopellet was re-suspended in
Buffer B and analyzed by WB.
Mitopellet for WB analysis of Cytochrome C release was
obtained as follows: Petri dishes (10 cm f) were transfected
with 700 ng of SOD1 and 700 ng of Bcl-2 using Lipofecta-
mine 2000 following the manufacturer’s instructions. After
24 h, cells were detached, washed with 1 ml of PBS, pelletted
at 500 rpm and lysed in 100 ml of digitonin extraction buffer
(0.025% digitonin, 250 mM sucrose, 10 mM KCl, 1.5 mM
MgCl2,1 m M EDTA, 1 mM EGTA, 20 mM HEPES at pH
7.5) supplemented with complete protease inhibitor (Roche).
Lysates were then spun at 15 000 rpm and the resulting
pellet containing mitochondria was lysed in 100 ml of RIPA
buffer and 20 mg of proteins were loaded onto 15% polyacryl-
amide gels. WB was then performed using antibodies against
Cytochrome C (Cell Signaling, Danvers, MA, USA) or Bcl-2
(BD, San Jose, CA).
Immunoﬂuorescence analysis of mitochondrial integrity
HEK293T cells were plated in two-chamber slides (Lab-Tek)
and transfected the following day with 200 ng of SOD1s-eGFP
or eGFP alone and 200 ng of Bcl-2 or pcDNA3 alone using
Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA) follow-
ing the manufacturer’s instructions. Immunolabeling was per-
formed by ﬁxing the cells for 20 min with a solution of 2%
paraformaldehyde/2% sucrose, 10 min with ice-cold methanol,
one wash in PBS and 1 h blocking in PBS/5% FBS (Blocking
Buffer, BB). Slides were then incubated with primary rabbit
antibody anti-Bcl-2 (1:200, Millipore, Billerica, MA, USA),
ﬂuorescent-conjugated mouse anti-Cytochrome C (25 ml/
well, Alexa Fluor 546, Invitrogen) and secondary anti-rabbit
Alexa Fluor 405 (1:200, Invitrogen) for 1 h in BB and
rinsed three times in PBS. Cells were then mounted in a sol-
ution of 60% glycerol, dried for 2 h, nailpolished and analyzed
by confocal microscopy.
Electron microscopy of mitochondrial morphology
Samples were ﬁxed in 2% gluteraldehyde with 1% tannic acid
buffered in phosphate buffer (pH 7.4) for o/n at 58C, rinsed in
the same buffer and then exposed to 2% osmium teteraoxide.
Following a rinse with double distilled water, samples were
put in 0.5% uranyl acetate and then dehydrated in graded
steps of acetone (one wash at 25%, 50%, 75%, 95% and
three washes at 100%). Samples were then inﬁltrated with
Spurrs resin and polymerized in a 658C convection oven.
The blocks were thin sectioned (70nm) with a Diatome
diamond knife on a Leica UCT ultramicrotome, sections ana-
lyzed in a FEI Tecnai 12T Electron Microscope and images
were digitally recorded with an AMT XR111 camera.
Generation of Bcl-2(AAA)
Generation of Bcl-2(AAA) harboring the triple mutation
GDD-AAA at position 101–103 was obtained by amplifying
the template plasmid pcDNA3/Bcl-2 with primers F
5′-CCGCCAAGCCGCCGCCGCCTTCTCCCGCC-3′ and R
5′-GGCGGGAGAAGGCGGCGGCGGCTTGGCGG-3′ using
Stratagene QuikChange Lightning kit following the manufac-
turer’s instructions (La Jolla, CA, USA).
Immunoprecipitation
SH-SY5Y cells (ATCC cat. # CRL-2266), mouse and human
spinal cords were lysed/homogenized in Chaps Buffer (1%
CHAPS, 14.5 mM KCl, 5 mM MgCl2,1 m M EGTA, 1 mM
EDTA, 20 mM Tris–HCl pH 7.5) with protease inhibitors
(Complete TM, Roche) Samples were pre-cleared for 4 h at
48C with Biomag magnetic beads (New England Biolabs,
Ipswich, MA) and then incubated with anti-Bcl-2 antibodies
(a-Bcl-2 Calbiochem, Gibbstown, NJ, a-BH3 Abgent, San
Diego, CA and a -pocket BD Pharmingen, San Jose, CA)
overnight at 48C. The antibody–antigen complex was then
precipitated with the beads for 4 h at 48C and precipitates
were analyzed by WB using a-Bcl-2 (BD Pharmingen and
Santa Cruz, CA). For co-immunoprecipitation, HEK293T
cells were lysed in RIPA buffer and 500 mg of lysates were
pre-cleared for 4 h at 48C with magnetic beads (New
England Biolabs, Ipswich, MA) and then incubated with the
anti-SOD1 antibody (a-SOD1, Santa Cruz, CA) overnight.
The antibody–antigen complex was then precipitated with
magnetic beads for 4 h at 48C and precipitates were analyzed
by WB using a-Bcl-2 (BD Pharmingen).
Cell viability assay
HEK293T cells were plated into 96 well plates and transfected
with either SOD1-eGFP (G93A) alone or in combination with
Bcl-2 as described above. Twenty-four hours after transfec-
tion, cell viability was scored using the CellTiter-Glo Lumi-
nescence Viability Assay (Promega, USA) following the
manufacturer’s instructions.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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